Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.7222 USD 4.09% Market Closed
Market Cap: 164.3m USD
Have any thoughts about
Vaxart Inc?
Write Note

Intrinsic Value

VXRT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VXRT stock under the Base Case scenario is 0.6969 USD. Compared to the current market price of 0.7222 USD, Vaxart Inc is Overvalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VXRT Intrinsic Value
0.6969 USD
Overvaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Vaxart Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VXRT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VXRT?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Vaxart Inc

Provide an overview of the primary business activities
of Vaxart Inc.

What unique competitive advantages
does Vaxart Inc hold over its rivals?

What risks and challenges
does Vaxart Inc face in the near future?

Has there been any significant insider trading activity
in Vaxart Inc recently?

Summarize the latest earnings call
of Vaxart Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Vaxart Inc.

Provide P/S
for Vaxart Inc.

Provide P/E
for Vaxart Inc.

Provide P/OCF
for Vaxart Inc.

Provide P/FCFE
for Vaxart Inc.

Provide P/B
for Vaxart Inc.

Provide EV/S
for Vaxart Inc.

Provide EV/GP
for Vaxart Inc.

Provide EV/EBITDA
for Vaxart Inc.

Provide EV/EBIT
for Vaxart Inc.

Provide EV/OCF
for Vaxart Inc.

Provide EV/FCFF
for Vaxart Inc.

Provide EV/IC
for Vaxart Inc.

Show me price targets
for Vaxart Inc made by professional analysts.

What are the Revenue projections
for Vaxart Inc?

How accurate were the past Revenue estimates
for Vaxart Inc?

What are the Net Income projections
for Vaxart Inc?

How accurate were the past Net Income estimates
for Vaxart Inc?

What are the EPS projections
for Vaxart Inc?

How accurate were the past EPS estimates
for Vaxart Inc?

What are the EBIT projections
for Vaxart Inc?

How accurate were the past EBIT estimates
for Vaxart Inc?

Compare the revenue forecasts
for Vaxart Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Vaxart Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Vaxart Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Vaxart Inc compared to its peers.

Compare the P/E ratios
of Vaxart Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Vaxart Inc with its peers.

Analyze the financial leverage
of Vaxart Inc compared to its main competitors.

Show all profitability ratios
for Vaxart Inc.

Provide ROE
for Vaxart Inc.

Provide ROA
for Vaxart Inc.

Provide ROIC
for Vaxart Inc.

Provide ROCE
for Vaxart Inc.

Provide Gross Margin
for Vaxart Inc.

Provide Operating Margin
for Vaxart Inc.

Provide Net Margin
for Vaxart Inc.

Provide FCF Margin
for Vaxart Inc.

Show all solvency ratios
for Vaxart Inc.

Provide D/E Ratio
for Vaxart Inc.

Provide D/A Ratio
for Vaxart Inc.

Provide Interest Coverage Ratio
for Vaxart Inc.

Provide Altman Z-Score Ratio
for Vaxart Inc.

Provide Quick Ratio
for Vaxart Inc.

Provide Current Ratio
for Vaxart Inc.

Provide Cash Ratio
for Vaxart Inc.

What is the historical Revenue growth
over the last 5 years for Vaxart Inc?

What is the historical Net Income growth
over the last 5 years for Vaxart Inc?

What is the current Free Cash Flow
of Vaxart Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Vaxart Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Vaxart Inc

Current Assets 71.5m
Cash & Short-Term Investments 62.6m
Receivables 4.8m
Other Current Assets 4.2m
Non-Current Assets 42.2m
PP&E 32.9m
Intangibles 8.4m
Other Non-Current Assets 851k
Current Liabilities 15.8m
Accounts Payable 3.6m
Accrued Liabilities 8.7m
Other Current Liabilities 3.5m
Non-Current Liabilities 18m
Long-Term Debt 1.6m
Other Non-Current Liabilities 16.4m
Efficiency

Earnings Waterfall
Vaxart Inc

Revenue
13.9m USD
Operating Expenses
-89m USD
Operating Income
-75m USD
Other Expenses
-612k USD
Net Income
-75.7m USD

Free Cash Flow Analysis
Vaxart Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Vaxart's Q2 2024 revenue rose to $6.4 million, up from $1.4 million in Q2 2023, primarily due to a BARDA contract. They received a $64.7 million payment post-quarter-end, supporting the upcoming COVID-19 Phase IIb trial, anticipated to start in the latter half of 2024, pending FDA alignment. Norovirus program discussions with the FDA are ongoing, with positive recent trial results. Vaxart ended the quarter with $62.6 million in cash and equivalents and expects a cash runway into 2026.

What is Earnings Call?
Fundamental Scores

VXRT Profitability Score
Profitability Due Diligence

Vaxart Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
29/100
Profitability
Score

Vaxart Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

VXRT Solvency Score
Solvency Due Diligence

Vaxart Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
66/100
Solvency
Score

Vaxart Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VXRT Price Targets Summary
Vaxart Inc

Wall Street analysts forecast VXRT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VXRT is 4.93 USD with a low forecast of 2.525 USD and a high forecast of 8.4 USD.

Lowest
Price Target
2.525 USD
250% Upside
Average
Price Target
4.93 USD
583% Upside
Highest
Price Target
8.4 USD
1 063% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VXRT?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for VXRT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VXRT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

VXRT News

Other Videos

Profile

Vaxart Inc Logo
Vaxart Inc

Country

United States of America

Industry

Biotechnology

Market Cap

164.3m USD

Dividend Yield

0%

Description

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

Contact

CALIFORNIA
South San Francisco
170 Harbor Way, Suite 300
+16505503500.0
vaxart.com

IPO

1980-03-17

Employees

110

Officers

Senior VP & Chief Scientific Officer
Dr. Sean N. Tucker Ph.D.
Chief Medical Officer
Dr. James F. Cummings M.D.
President, CEO & Director
Mr. Steven Lo
CFO, Principal Financial Officer & Principal Accounting Officer
Mr. Phillip Eric Lee
Chief Technology Officer
Dr. Raymond D. Stapleton Jr., Ph.D.
Senior VP & General Counsel
Mr. Edward B. Berg
Show More
Senior Vice President of Clinical Development & Project Management
Ms. Shaily Jaini Garg
Senior Vice President of Quality
Dr. Rajesh Kapoor Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one VXRT stock?

The intrinsic value of one VXRT stock under the Base Case scenario is 0.6969 USD.

Is VXRT stock undervalued or overvalued?

Compared to the current market price of 0.7222 USD, Vaxart Inc is Overvalued by 4%.

Back to Top